HRP20241162T1 - Farmaceutski pripravci koji sadrže (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-4-il) oksi)metil)benzil)piperazin-1-il)-3-fluorobenzonitril i postupci za njihovu uporabu - Google Patents
Farmaceutski pripravci koji sadrže (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-4-il) oksi)metil)benzil)piperazin-1-il)-3-fluorobenzonitril i postupci za njihovu uporabu Download PDFInfo
- Publication number
- HRP20241162T1 HRP20241162T1 HRP20241162TT HRP20241162T HRP20241162T1 HR P20241162 T1 HRP20241162 T1 HR P20241162T1 HR P20241162T T HRP20241162T T HR P20241162TT HR P20241162 T HRP20241162 T HR P20241162T HR P20241162 T1 HRP20241162 T1 HR P20241162T1
- Authority
- HR
- Croatia
- Prior art keywords
- approximately
- amount
- weight
- mannitol
- optionally
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims 15
- 238000000034 method Methods 0.000 title 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 15
- 229930195725 Mannitol Natural products 0.000 claims 15
- 239000000594 mannitol Substances 0.000 claims 15
- 235000010355 mannitol Nutrition 0.000 claims 15
- 229920002472 Starch Polymers 0.000 claims 10
- 229920002678 cellulose Polymers 0.000 claims 10
- 239000001913 cellulose Substances 0.000 claims 10
- 235000010980 cellulose Nutrition 0.000 claims 10
- 239000008107 starch Substances 0.000 claims 10
- 229940032147 starch Drugs 0.000 claims 10
- 235000019698 starch Nutrition 0.000 claims 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 9
- 229920003109 sodium starch glycolate Polymers 0.000 claims 9
- 229940079832 sodium starch glycolate Drugs 0.000 claims 9
- 239000008109 sodium starch glycolate Substances 0.000 claims 9
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 229940125904 compound 1 Drugs 0.000 claims 7
- 235000021355 Stearic acid Nutrition 0.000 claims 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 6
- 239000008117 stearic acid Substances 0.000 claims 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063048998P | 2020-07-07 | 2020-07-07 | |
| EP21755119.1A EP4178548B1 (en) | 2020-07-07 | 2021-07-06 | Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)m ethyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| PCT/US2021/040452 WO2022010854A1 (en) | 2020-07-07 | 2021-07-06 | Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)m ethyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241162T1 true HRP20241162T1 (hr) | 2024-11-22 |
Family
ID=77338767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241162TT HRP20241162T1 (hr) | 2020-07-07 | 2021-07-06 | Farmaceutski pripravci koji sadrže (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-4-il) oksi)metil)benzil)piperazin-1-il)-3-fluorobenzonitril i postupci za njihovu uporabu |
Country Status (22)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120004860A (zh) * | 2020-07-20 | 2025-05-16 | 江苏恒瑞医药股份有限公司 | 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| PY0323128A (es) | 2002-09-10 | 2012-12-03 | Pharmacia Italia Spa | Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| AU2016213879B2 (en) | 2009-05-19 | 2017-11-16 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| CA2772275A1 (en) | 2009-09-18 | 2011-03-24 | Sanofi | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| SMT201900071T1 (it) | 2011-07-28 | 2019-02-28 | Rigel Pharmaceuticals Inc | Nuove formulazioni di (trimetossifenilammino)pirimidinile |
| TWI782395B (zh) | 2016-01-08 | 2022-11-01 | 美商西建公司 | 抗增生化合物,及其醫藥組合物及用途 |
| JP7258009B2 (ja) * | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| PL3796912T3 (pl) | 2018-05-23 | 2023-09-11 | Celgene Corporation | Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego |
| IL278854B2 (en) | 2018-05-23 | 2026-01-01 | Celgene Corp | Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile |
| CN108502097B (zh) | 2018-05-24 | 2023-06-30 | 江苏科技大学 | 一种可开闭月池挡板装置 |
| AU2020206692B2 (en) | 2019-01-09 | 2025-03-27 | Celgene Corporation | Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
-
2021
- 2021-07-06 ES ES21755119T patent/ES2988714T3/es active Active
- 2021-07-06 CN CN202180048076.XA patent/CN115867261B/zh active Active
- 2021-07-06 US US18/014,882 patent/US12472176B2/en active Active
- 2021-07-06 CA CA3184460A patent/CA3184460A1/en active Pending
- 2021-07-06 ES ES24179296T patent/ES3068915T3/es active Active
- 2021-07-06 EP EP21755119.1A patent/EP4178548B1/en active Active
- 2021-07-06 SM SM20240374T patent/SMT202400374T1/it unknown
- 2021-07-06 JP JP2023501163A patent/JP7868025B2/ja active Active
- 2021-07-06 RS RS20241101A patent/RS66027B1/sr unknown
- 2021-07-06 EP EP24179296.9A patent/EP4438043B1/en active Active
- 2021-07-06 KR KR1020237003869A patent/KR20230035598A/ko active Pending
- 2021-07-06 WO PCT/US2021/040452 patent/WO2022010854A1/en not_active Ceased
- 2021-07-06 PT PT217551191T patent/PT4178548T/pt unknown
- 2021-07-06 IL IL299657A patent/IL299657A/en unknown
- 2021-07-06 DK DK21755119.1T patent/DK4178548T3/da active
- 2021-07-06 HR HRP20241162TT patent/HRP20241162T1/hr unknown
- 2021-07-06 BR BR112023000248A patent/BR112023000248A2/pt unknown
- 2021-07-06 FI FIEP21755119.1T patent/FI4178548T3/fi active
- 2021-07-06 MX MX2023000292A patent/MX2023000292A/es unknown
- 2021-07-06 AU AU2021305052A patent/AU2021305052A1/en active Pending
- 2021-07-06 HU HUE21755119A patent/HUE068476T2/hu unknown
- 2021-07-06 PL PL21755119.1T patent/PL4178548T3/pl unknown
- 2021-07-06 LT LTEPPCT/US2021/040452T patent/LT4178548T/lt unknown
- 2021-07-06 SI SI202130179T patent/SI4178548T1/sl unknown
-
2025
- 2025-10-15 US US19/359,015 patent/US20260034122A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4438043A3 (en) | 2024-11-27 |
| EP4178548A1 (en) | 2023-05-17 |
| SI4178548T1 (sl) | 2024-10-30 |
| RS66027B1 (sr) | 2024-11-29 |
| DK4178548T3 (da) | 2024-08-19 |
| IL299657A (en) | 2023-03-01 |
| CN115867261A (zh) | 2023-03-28 |
| JP7868025B2 (ja) | 2026-06-01 |
| WO2022010854A1 (en) | 2022-01-13 |
| EP4438043C0 (en) | 2026-02-25 |
| JP2023533314A (ja) | 2023-08-02 |
| PL4178548T3 (pl) | 2024-11-12 |
| EP4178548B1 (en) | 2024-07-24 |
| HUE068476T2 (hu) | 2024-12-28 |
| LT4178548T (lt) | 2024-09-25 |
| MX2023000292A (es) | 2023-02-09 |
| PT4178548T (pt) | 2024-10-22 |
| SMT202400374T1 (it) | 2024-11-15 |
| ES2988714T3 (es) | 2024-11-21 |
| KR20230035598A (ko) | 2023-03-14 |
| US20260034122A1 (en) | 2026-02-05 |
| FI4178548T3 (fi) | 2024-08-14 |
| US20230270742A1 (en) | 2023-08-31 |
| AU2021305052A1 (en) | 2023-02-09 |
| EP4438043B1 (en) | 2026-02-25 |
| CN115867261B (zh) | 2025-05-23 |
| CA3184460A1 (en) | 2022-01-13 |
| ES3068915T3 (en) | 2026-06-03 |
| EP4438043A2 (en) | 2024-10-02 |
| US12472176B2 (en) | 2025-11-18 |
| BR112023000248A2 (pt) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2535810C (en) | Tablet containing 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester or the salts thereof | |
| RS66565B1 (sr) | Farmaceutska kombinacija, kompozicija i kombinovani preparat koji sadrži aktivator glukokinaze i inhibitor sglt-2 i postupci njihove pripreme i upotrebe | |
| US20010047000A1 (en) | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure | |
| HRP20231670T1 (hr) | Farmaceutski pripravak za oralnu primjenu koji sadrži derivat aminopirimidina ili njegovu sol | |
| HRP20130738T1 (hr) | Postupak lijeäśenja ili profilakse | |
| HRP20200379T1 (hr) | Spojevi pirimidindiona protiv srčanih stanja | |
| DK2665471T3 (en) | ORAL PHARMACEUTICAL DOSAGE FORMS WITH MANAGED RELEASE COMPREHENSIVE MGBG | |
| JP2007501281A5 (cg-RX-API-DMAC7.html) | ||
| CN101247832A (zh) | 含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的药物制剂 | |
| US20140112962A1 (en) | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant | |
| KR20130083903A (ko) | 저장 안정성 제제를 제조하기 위한 결합제의 용도 | |
| TR202008542A2 (tr) | Li̇nagli̇pti̇n ve metformi̇n i̇çeren fi̇lm kapli tablet hazirlama prosesi̇ | |
| KR101750690B1 (ko) | 메트포르민 및 로베글리타존을 포함하는 약제학적 조성물 | |
| CZ268896A3 (en) | Pharmaceutical preparation for treating diabetic nephropathy and application of angiotensin ii antagonist for preparing thereof | |
| HRP20250002T1 (hr) | Ampreloksetin, namijenjen upotrebi u liječenju neurogene ortostatske hipotenzije | |
| TW201427661A (zh) | 含有鈣拮抗劑及血管張力素ii受體拮抗劑之醫藥製劑 | |
| KR20120014583A (ko) | 타르타르산 염 형태의 데스페소테로딘 | |
| EP2867199A2 (en) | Stable compositions of fesoterodine | |
| TW201427720A (zh) | 含有鈣拮抗劑及血管張力素ii受體拮抗劑之醫藥製劑之製造方法 | |
| JP2019123703A (ja) | ダサチニブを有効成分とする医薬錠剤及びその製造方法 | |
| FI4178548T3 (fi) | (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-yyli)-1-oksoisoindolin-4-yyl)oksi)metyyli)bentsyyli)piperatsin-1-yyli)-3-fluoribentsonitriiliä käsittäviä lääkekoostumuksia ja niiden käyttötapoja | |
| AU2011270133B2 (en) | Sustained-release therapeutic agent for hypertension and renal dysfunction | |
| JP6883401B2 (ja) | アジルサルタン含有錠剤及び錠剤におけるアジルサルタンの安定化方法 | |
| JP2023551249A5 (cg-RX-API-DMAC7.html) | ||
| CN102802630A (zh) | 通过神经元烟碱受体配体逆转左旋多巴诱导的运动障碍 |